Three Phase II Studies Evaluate the Combination of REVLIMID and rituximab in Patients with Indolent Non-Hodgkin's Lymphoma

Combinationof REVLIMID/Rituximab Achieved Response Rates of:

• 75% in Patients with Relapsed/Refractory Indolent Disease
• 53% in Patients Previously Resistant to Rituximab
• 86% in Front-Line Indolent non-Hodgkin's lymphoma

94% Complete Response in Patients with Front-Line Follicular Lymphoma

Celgene International Sàrl (NASDAQ: CELG) announced that investigational data evaluating combination therapy with REVLIMID(lenalidomide) and rituximab in patients with indolent non-Hodgkin's lymphoma (NHL) were presented during the 51^st American Society of Hematology's annual meeting in New Orleans, LA. The phase II investigator-initiated studies explored the potential clinical synergy of these two agents in patients with indolent NHL, which includes patients with the follicular lymphoma histologic subtype.

The first study, led by Joseph Tuscano, MD and presented by Mrinal Dutia, MD both from University of California-Davis Cancer Center, evaluated the REVLIMID plus rituximab combination in patients with relapsed/refractory indolent NHL. All 16 patients on study had received a median of three prior therapies, which included either rituximab or rituximab-containing chemotherapy regimens. In this study, the preliminary overall response rate (ORR) is 75% (12 out of 16 patients), including 31% of patients (n=5) who achieved a complete response (confirmed or unconfirmed; CR/CRu). In 13 patients with relapsed or refractory follicular NHL, there were 11 responders (85% ORR), of whom five patients (38%) achieved a complete response.

Most common Grade 3 or 4 adverse events included fatigue (12%), neutropaenia(18%), lymphopaenia (25%) and hyponatraemia (18%). Two cases of tumour lysis syndrome (both in patients not receiving prophylaxis) were managed by reducing the dose to 20 mg per day and employing standard prophylaxis.

The second study, led by Stephen Schuster, MD and presented by Tahamlan Ahmadi, MD, PhD both from the Abramson Cancer Center, University of Pennsylvania, assessed the effects of extended treatment with REVLIMID^® plus low-dose dexamethasone with four weekly doses of rituximab added in Cycle 3 in 24 patients with indolent B-cell or mantle cell lymphomas who are resistant to rituximab. Among 15 of 24 patients who completed five cycles of therapy by the time of the analysis, the preliminary ORR was 53%, including 33% of patients who achieved a CR. At a median follow-up of 10.9 months, 86% of patients disease had not progressed.

Among these 15 patients, the most common Grade 3 or 4 non-haematologic adverse events were hypokalemia (13%), hypophosphataemia (13%), pulmonary embolism (7%), pneumonia (20%) and hypocalcaemia (7% patients). Grade 1 tumour flare occurred in one patient with follicular lymphoma,and no cases of tumour lysis syndrome occurred.

The third study led by Felipe Samaniego, MD and presented by Nathan Fowler, MD both from the Department of Lymphoma and Myeloma, MD Anderson Cancer Center, assessed the clinical efficacy and safety of the REVLIMD and rituximab combination in front-line therapy in 30 patients with stage III or IV indolent B-cell NHL. The study reported results for the first 28 patients with NHL subtypes, which included 17 patients with follicular lymphoma, eight patients with marginal zone lymphoma, and three patients with small lymphocytic lymphoma. Twenty-four patients (86%) responded to therapy including 21 patients (75%) who achieved a CR/Cru. Of note, these investigators reported that 16 of 17 patients (94%) with follicular lymphoma achieved a CR/CRu after completing six cycles of therapy.

In this study, the most common Grade 3 or 4 adverse events were rash (20%), neutropaenia (23%), and myalgia (13%) among 30 patients who were evaluated for toxicity. No patients developed tumor lysis syndrome.

Side effects associated with the REVLIMID plus rituximab combination were consistent between the studies evaluating this therapy, and not significantly different from that observed with REVLIMID alone. Tumour lysis was not observed in patients who received standard tumour lysis prophylaxis.

About REVLIMID
REVLIMID is an IMiDs^® compound. REVLIMID and other IMiDs continue to be evaluated in over 100 clinical trials. The IMiDs pipeline is covered by a comprehensive intellectual property estate of issued and pending patent applications in the US, EU and other regions, including composition-of- matter and use patents.

REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in nearly 50 countries, encompassing Europe, the Americas, the Middle-East and Asia, and in combination with dexamethasone for the treatment of patients whose disease has progressed after one therapy in Australia and New Zealand. REVLIMID is available through a restricted distribution programme.

REVLIMID is also approved in the United States, Canada and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anaemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Marketing Authorisation Applications are currently being evaluated in a number of other countries.

Important Safety Information
REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.

REVLIMID® (lenalidomide) is indicated for patients with transfusion-dependent anaemia due to Low- or Intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

WARNINGS:

1. POTENTIAL FOR HUMAN BIRTH DEFECTS.

LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY. FEMALES SHOULD BE ADVISED TO AVOID PREGNANCY WHILE TAKING REVLIMID^® (lenalidomide).

Special Prescribing Requirements

BECAUSE OF THIS POTENTIAL TOXICITY AND TO AVOID FETAL EXPOSURE TO REVLIMID^® (lenalidomide), REVLIMID^® (lenalidomide) IS ONLY AVAILABLE UNDER A SPECIAL RESTRICTED DISTRIBUTION PROGRAM. THIS PROGRAM IS CALLED "RevAssist^®". UNDER THIS PROGRAM, ONLY PRESCRIBERS AND PHARMACISTS REGISTERED WITH THE PROGRAM CAN PRESCRIBE AND DISPENSE THE PRODUCT. IN ADDITION, REVLIMID^®(lenalidomide) MUST ONLY BE DISPENSED TO PATIENTS WHO ARE REGISTERED AND MEET ALL THE CONDITIONS OF THE RevAssist^® PROGRAM.

2. HEMATOLOGIC TOXICITY (NEUTROPENIA AND THROMBOCYTOPENIA).

THIS DRUG IS ASSOCIATED WITH SIGNIFICANT NEUTROPENIA AND THROMBOCYTOPENIA.EIGHTY PERCENT OF PATIENTS WITH DEL 5q MYELODYSPLASTIC SYNDROMES HAD TO HAVE A DOSE DELAY/REDUCTION DURING THE MAJOR STUDY. THIRTY-FOUR PERCENT OF PATIENTS HAD TO HAVE A SECOND DOSE DELAY/REDUCTION. GRADE 3 OR 4 HEMATOLOGIC TOXICITY WAS SEEN IN 80% OF PATIENTS ENROLLED IN THE STUDY. PATIENTS ON THERAPY FOR DEL 5q MYELODYSPLASTIC SYNDROMES SHOULD HAVE THEIR COMPLETE BLOOD COUNTS MONITORED WEEKLY FOR THE FIRST 8 WEEKS OF THERAPY AND AT LEAST MONTHLY THEREAFTER. PATIENTS MAY REQUIRE DOSE INTERRUPTION AND/OR REDUCTION. PATIENTS MAY REQUIRE USE OF BLOOD PRODUCT SUPPORT AND/OR GROWTH FACTORS. (SEE DOSAGE AND ADMINISTRATION)

3. DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM.

THIS DRUG HAS DEMONSTRATED A SIGNIFICANTLY INCREASED RISK OF DEEP VENOUS THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WITH MULTIPLE MYELOMA WHO WERE TREATED WITH REVLIMID^® (lenalidomide) COMBINATION THERAPY. PATIENTS AND PHYSICIANS ARE ADVISED TO BE OBSERVANT FOR THE SIGNS AND SYMPTOMS OF THROMBOEMBOLISM. PATIENTS SHOULD BE INSTRUCTED TO SEEK MEDICAL CARE IF THEY DEVELOP SYMPTOMS SUCH AS SHORTNESS OF BREATH, CHEST PAIN, OR ARM OR LEG SWELLING. IT IS NOT KNOWN WHETHER PROPHYLACTIC ANTICOAGULATION OR ANTIPLATELET THERAPY PRESCRIBED IN CONJUNCTION WITH REVLIMID^® (lenalidomide) MAY LESSEN THE POTENTIAL FOR VENOUS THROMBOEMBOLIC EVENTS. THE DECISION TO TAKE PROPHYLACTIC MEASURES SHOULD BE DONE CAREFULLY AFTER AN ASSESSMENT OF AN INDIVIDUAL PATIENT'S UNDERLYING RISK FACTORS.

You can get the information about REVLIMID^® (lenalidomide) and the RevAssist^® program on the Internet at www.REVLIMID.com or by calling the manufacturer's toll-free number at 1-888-423-5436.

Additional Warnings: Haematologic Toxicity

Multiple Myeloma
In the pooled multiple myeloma studies, Grade 3 and 4 haematologic toxicities were more frequent in patients treated with the combination of REVLIMID® (lenalidomide) and dexamethasone than in patients treated with dexamethasone alone. Patients on therapy should have their complete blood counts monitored every 2 weeks for the first 12 weeks and then monthly thereafter. Patients may require dose interruption and/or dose reduction.

Contraindications:
Hypersensitivity: REVLIMID® (lenalidomide) is contraindicated in any patients who have demonstrated hypersensitivity to the drug or its components.

Precautions:
Renal impairment: Since lenalidomide is primarily excreted unchanged by the kidney, adjustments to the starting dose of REVLIMID® (lenalidomide) are recommended to provide appropriate drug exposure in patients with moderate or severe (CLcr < 60 mL/min) renal impairment and in patients on dialysis. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it would be prudent to monitor renal function.

Nursing mothers: It is not known whether REVLIMID® (lenalidomide) is excreted in human milk. Because of the potential for adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.

Adverse Reactions:
Multiple Myeloma
In the REVLIMID® (lenalidomide)/dexamethasone treatment group, 151 patients (45%) underwent at least one dose interruption with or without a dose reduction of REVLIMID® (lenalidomide) compared to 21% in the placebo/dexamethasone treatment group. Of these patients who had one dose interruption with or without a dose reduction, 50% in the REVLIMID® (lenalidomide)/dexamethasone treatment group underwent at least one additional dose interruption with or without a dose reduction compared to 21% in the placebo/dexamethasone treatment group. Most adverse events and Grade 3/4 adverse events were more frequent in MM patients who received the combination of REVLIMID® (lenalidomide)/dexamethasone compared to placebo/dexamethasone.

Other adverse events reported in multiple myeloma patients (REVLIMID® (lenalidomide)/dexamethasone vs dexamethasone/placebo): constipation (39% vs 19%), fatigue (38% vs 37%), insomnia (32% vs 37%), muscle cramp (30% vs 21%), diarrhea (29% vs 25%), neutropenia (28% vs 5%), anemia (24% vs 17%), asthenia (23% vs 25%), pyrexia (23% vs 19%), nausea (22% vs 19%), headache (21% vs 21%), peripheral edema (21% vs 19%), dizziness (21% vs 15%), dyspnea (20% vs 15%), tremor (20% vs 7%), decreased weight (18% vs 14%), thrombocytopenia (17% vs 10%), rash (16% vs 8%), back pain (15% vs 14%), hyperglycemia (15% vs 14%), and muscle weakness (15% vs 15%).

Myelodysplastic Syndromes

Thrombocytopenia (61.5%; 91/148) and neutropenia (58.8%; 87/148) were the most frequently reported adverse events observed in the del 5q MDS population. Other adverse reactions reported in del 5q MDS patients (REVLIMID® (lenalidomide)): diarrhea (49%), pruritus (42%), rash (36%), fatigue (31%), constipation (24%), nausea (24%), nasopharyngitis (23%), arthralgia (22%), pyrexia (21%), back pain (21%), peripheral edema (20%), cough (20%), dizziness (20%), headache (20%), muscle cramp (18%), dyspnea (17%), and pharyngitis (16%).

Dosage and Administration:
Dosing is continued or modified based upon clinical and laboratory findings. Dosing modifications are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicity judged to be related to REVLIMID® (lenalidomide). For other Grade 3 or 4 toxicities judged to be related to REVLIMID®(lenalidomide), hold treatment and restart at next lower dose level when toxicity has resolved to less than or equal to Grade 2.

Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

About Non-Hodgkin's Lymphoma
Lymphoma is the name for the group of blood cancers that start in the lymphatic system, which is part of the body's immune system. Lymphomas generally start in the lymph nodes or outside of lymph nodes within the lymphatic tissues located around organs such as the stomach or intestines. They may involve the marrow and the blood in some cases as well. There are many different kinds of non-Hodgkin's lymphoma.

About Celgene International Sàrl
Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialisation of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control. The Company's actual results, performance, or achievements could be materially different from those projected by these forward-looking statements.The factors that could cause actual results, performance, or achievements to differ from the forward-looking statements are discussed in the Company's filings with the Securities and Exchange Commission, such as the Company's Form 10-K, 10-Q and 8-K reports.Given these risks and uncertainties, you are cautioned not to place undue reliance on the forward-looking statements.

Contacts:

Celgene International Sàrl
Kevin Loth
Director of External Relations
[phone]